Gaurav Tyagi, MD
Interventional Cardiology · Wichita, KSNPI 1306161500
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,942 of the $13,166 with a category attached, or 75.5%. 32 manufacturers reported payments, led by Angiodynamics, Inc. at 25.0% of the total. Reporting peaked in 2023 at $5,629 and has fallen 81.3% since, to $1,050 in 2025.
Across 219 payments — averaging $60.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$3K
- Abbott$2K
- Edwards Lifesciences$2K
- Medtronic$2K
- Abiomed$2K
- Cvrx, Inc.$342
- plus $2K from 26 others
What the payments were for
- Travel & lodging$3,08823%
- Food & beverage$9,94276%
- Education$1361%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 8 | $3,291 |
| Abbott | 38 | $2,099 |
| Edwards Lifesciences | 19 | $1,903 |
| Medtronic(2 entities) | 37 | $1,840 |
| Abiomed | 19 | $1,716 |
| Cvrx, Inc. | 4 | $342 |
| AstraZeneca | 21 | $300 |
| Inari Medical, Inc. | 2 | $223 |
| Boston Scientific | 5 | $212 |
| Amgen | 10 | $160 |
| Johnson & Johnson | 2 | $129 |
| Novo Nordisk | 5 | $99 |
| Merck | 6 | $92 |
| Boehringer Ingelheim | 6 | $87 |
| Novartis | 3 | $87 |
| Pfizer | 6 | $81 |
| Philips North America LLC | 1 | $75 |
| E.r. Squibb & Sons, L.L.C. | 4 | $61 |
| Esperion Therapeutics, Inc. | 3 | $60 |
| Sanofi-aventis U.S. LLC | 4 | $60 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $34 |
| Amarin Pharma, Inc. | 2 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Surmodics, Inc. | 3 | $23 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $23 |
| Cardiva Medical, Inc. | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $21 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| CSL Behring | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $14 |
| Livanova USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AngioVac$3,262
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,118
- Impella$725
- CardioMEMS HF System$404
- Micra$388
- AVEIR$254
- Barostim Neo System$247
- FLOWTRIEVER CATHETER, S$223
- CT THROMBECTOMY SYSTEM KIT$223
- COREVALVE EVOLUT R$170
- ASSURITY$156
- PRESSUREWIRE$135
- Confirm Rx$128
- ALLURE QUADRA$123
- MitraClip$118
- RESOLUTE ONYX$116
- XARELTO$115
- ESPRIT$115
- CARDIOMEMS$107
How this compares
$13,166 in reported general payments places this provider in the 60th percentile of 55 interventional cardiology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 490 | $359,085 |
| EntrestoSacubitril/Valsartan | 147 | $121,215 |
| JardianceEmpagliflozin | 106 | $80,793 |
| XareltoRivaroxaban | 87 | $72,765 |
| BrilintaTicagrelor | 107 | $71,291 |
| Repatha SureclickEvolocumab | 95 | $69,082 |
| FarxigaDapagliflozin Propanediol | 44 | $26,957 |
| Praluent PenAlirocumab | 20 | $13,801 |
| Repatha SyringeEvolocumab | 22 | $10,984 |
| Bumetanide | 126 | $2,995 |
| Metoprolol Succinate | 390 | $2,741 |
| Ezetimibe | 203 | $2,678 |
| Atorvastatin Calcium | 569 | $2,407 |
| Midodrine Hcl | 12 | $2,389 |
| ClopidogrelClopidogrel Bisulfate | 324 | $1,981 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $81 | $359,085490 claims |
| NovartisEntresto | $87 | $121,215147 claims |
| AstraZenecaBrilinta, Farxiga | $300 | $98,247151 claims |
| Boehringer IngelheimJardiance | $87 | $80,793106 claims |
| Johnson & JohnsonXarelto | $129 | $72,76587 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 55 interventional cardiology providers in Kansas.
Other interventional cardiology in Wichita
- Maheedhar GedelaWichita$54K
- Hussam FarhoudWichita$25K
- Christian HouraniWichita$17K
- Ravi BajajWichita$10K
- Assem FarhatWichita$9K
- Venkata BoppanaWichita$9K
- Alaa BouladWichita$8K
- Rohma ShaikhWichita$4K
- George ReaderWichita$4K
- Mohamed ElmassryWichita$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.